We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Circulating Tumor Cell-Count Drives Therapy Choice for Breast Cancer

By LabMedica International staff writers
Posted on 18 Nov 2020
Print article
Image: The CELLSEARCH CTC System is the first and only clinically validated, FDA-cleared system for identification, isolation, and enumeration of circulating tumor cells (CTCs) from a simple blood test (Photo courtesy of Menarini Silicon Biosystems).
Image: The CELLSEARCH CTC System is the first and only clinically validated, FDA-cleared system for identification, isolation, and enumeration of circulating tumor cells (CTCs) from a simple blood test (Photo courtesy of Menarini Silicon Biosystems).
The choice between chemotherapy and endocrine therapy as first-line treatment for hormone receptor–positive, ERBB2 (also known as HER2)-negative metastatic breast cancer is usually based on the presence of clinical features associated with a poor prognosis.

Circulating Tumor Cell (CTC) test is a simple blood test that helps oncologists in assessing the prognosis of patients with metastatic breast, colorectal, or prostate cancer. A prespecified circulating tumor cell count (CTC) threshold appeared to be reliable for selecting treatment with chemotherapy instead of hormone therapy in women with a certain metastatic breast cancer phenotype, a non-inferiority trial indicated.

A team of Medical Oncologists led by those at the Paris-Saclay University (Saint-Cloud, France) studied 755 women with hormone receptor-positive, ERBB2-negative metastatic breast cancer who were randomly assigned to receive first-line treatment based on CTC count or treatment based on clinician choice. In the CTC-count arm, women with CTC count of 5 CTCs/7.5 mL or greater were automatically assigned to chemotherapy instead of endocrine therapy. Data were collected at 17 French cancer centers from February 1, 2012, to July 28, 2016, and analyzed June 2019 to October 2019. The CELLSEARCH CTC System (Menarini Silicon Biosystems, Bologna, Italy) was used to capture and isolate tumor cells circulating in the blood in all patients.

The scientists reported that among the 755 women in the per-protocol population, the median (range) age was 63 (30-88) years: 64 (30-88) years for the 377 patients allocated to the CTC arm and 63 (31-87) years for the 378 patients allocated to the standard arm; 138 (37%) and 103 (27%) received chemotherapy, respectively. Median progression-free survival (PFS) was 15.5 months (95% CI, 12.7-17.3) in the CTC arm and 13.9 months (95% CI, 12.2-16.3) in the standard arm. The primary end point was met, with a hazard ratio of 0.94 (90% CI, 0.81-1.09).

In addition, more than one-third of patients had discordant CTC and clinical assessments. When these patients with clinical low risk and high CTC counts were pooled with clinical high risk/low CTC counts in a multivariable analysis, PFS and overall survival were higher for those treated with chemotherapy versus endocrine therapy. Overall survival in the per-protocol population was 47.3 months (95% CI 43.8-51.3) in the CTC arm and 42.8 months (95% CI 39.5-47.4) in the standard arm.

Francois-Clement Bidard, MD, PhD, Professor of Medical Oncology and senior author of the study, said, “The use of the CTC count represents the first objective and reproducible decision tool to help physicians choose between hormone therapy or chemotherapy for this particular group of patients.”

The authors concluded that this randomized clinical trial found that the CTC count may be a reliable biomarker method for guiding the choice between chemotherapy and endocrine therapy as the first-line treatment in hormone receptor–positive, ERBB2-negative metastatic breast cancer. The study was published on November 5, 2020 in the journal JAMA Oncology.

Related Links:
Paris-Saclay University
Menarini Silicon Biosystems


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.